MediciNova/MNOV

$1.36

2.98%
-
1D1W1MYTD1YMAX

About MediciNova

MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

Ticker

MNOV

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Yuichi Iwaki

Employees

13

Headquarters

La jolla, United States

MediciNova Metrics

BasicAdvanced
$66M
Market cap
-
P/E ratio
-$0.17
EPS
0.70
Beta
-
Dividend rate
$66M
0.69531
$2.66
$1.26
35K
19.065
-12.55%
-13.18%
-13.06%
65.722
1.098
1.447
38.18%

What the Analysts think about MediciNova

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 2 analysts.
1,150% upside
High $28.00
Low $6.00
$1.36
Current price
$17.00
Average price target

MediciNova Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$2.7M
35%
Profit margin
0%
NaN%

MediciNova Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 20%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.06
-$0.01
-$0.04
-$0.06
-
Expected
-$0.07
-$0.08
-$0.08
-$0.05
-$0.06
Surprise
-14.29%
-87.5%
-50%
20%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for MediciNova stock?

MediciNova (MNOV) has a market cap of $66M as of May 29, 2024.

What is the P/E ratio for MediciNova stock?

The price to earnings (P/E) ratio for MediciNova (MNOV) stock is 0 as of May 29, 2024.

Does MediciNova stock pay dividends?

No, MediciNova (MNOV) stock does not pay dividends to its shareholders as of May 29, 2024.

When is the next MediciNova dividend payment date?

MediciNova (MNOV) stock does not pay dividends to its shareholders.

What is the beta indicator for MediciNova?

MediciNova (MNOV) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the MediciNova stock price target?

The target price for MediciNova (MNOV) stock is $17, which is 1159.26% above the current price of $1.35. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell MediciNova stock

Buy or sell MediciNova stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing